Pharmaceutical Technology on MSN7d
GSK to acquire Chimagen’s CMG1A46 for autoimmune diseaseGlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...
GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire ...
The deal with China’s Chimagen Biosciences is the latest example of pharma interest in exploring the potential of “T cell engagers” in autoimmune disease.
GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to ...
The candidate in question is CMG1A46, a dual CD19- and CD20-targeted T cell engager that Chimagen Biosciences is currently evaluating in phase 1 trials for leukemia and lymphoma. However, GSK has ...
UK pharma major GSK is to buy CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from privately-held ...
GSK inks agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline: London, UK Thursday, October 31, 2024, 10:00 Hrs [IST] GSK plc and Chimagen Bioscien ...
In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy ...
GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback